Oncotarget

Meta-Analysis:

The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis

Kun Liu, Shuo Gu, Xuzhong Liu, Qing Sun, Yunyan Wang, Junsong Meng and Zongyuan Xu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:72933-72938. https://doi.org/10.18632/oncotarget.18014

Metrics: PDF 1135 views  |   HTML 1777 views  |   ?  


Abstract

Kun Liu1,*, Shuo Gu1, Xuzhong Liu1, Qing Sun1, Yunyan Wang1, Junsong Meng1 and Zongyuan Xu1

1Department of Urology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China, 223300

*Co first author

Correspondence to:

Zongyuan Xu, email: [email protected]

Junsong Meng, email: [email protected]

Keywords: prostate cancer, matrix metalloproteinase 2, polymorphism, meta-analysis

Received: May 04, 2017     Accepted: May 10, 2017     Published: May 19, 2017

ABSTRACT

Prostate cancer is a common cancer in men. However, the association between the rs243865 single-nucleotide polymorphisms in the matrix metalloproteinase 2 gene (MMP2) and the risk for prostate cancer is inconclusive. We searched the PubMed, EMBASE, Cochrane Library, and the Chinese CNKI and WANFANG databases for the relevant literature. Data were extracted and pooled results were estimated from odds ratios (OR) with 95% confidence intervals (95% CIs). The quality of included studies was assessed, and publication bias of all included studies was examined. A total five studies involving 1895 patients with prostate cancer and 1918 controls were included. There was a significant association between rs243865 polymorphisms and higher risk of prostate cancer in the co-dominant model, dominant model, and allele model (CC vs. CT+TT, OR: 1.60, 95% CI: 1.22–2.11, P = 0.001; CC vs. CT, OR: 1.80, 95% CI: 1.34–2.42, P < 0.001; C vs. T, OR: 1.32, 95% CI: 1.05–1.66, P = 0.016, respectively). However, there was no significant difference between the co-recessive model and recessive model. Our meta-analysis results suggest that MMP2 rs243865 polymorphisms are significantly associated with higher risk of prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18014